Nonalcoholic fatty liver disease and non-liver comorbidities
Richie Manikat, Mindie H. Nguyen
Clin Mol Hepatol. 2023;29(Suppl):s86-s102.   Published online 2023 Jan 5     DOI: https://doi.org/10.3350/cmh.2022.0442
Citations to this article as recorded by Crossref logo
Comorbidities and Malignancy among NAFLD Patients Compared to the General Population, A Nation-Based Study
Naim Abu-Freha, Bracha Cohen, Michal Gordon, Sarah Weissmann, Alexander Fich, Daniela Munteanu, David Yardeni, Ohad Etzion
Biomedicines.2023; 11(4): 1110.     CrossRef
Implications of comorbidities in nonalcoholic fatty liver disease
Sherlot Juan Song, Vincent Wai-Sun Wong
Clinical and Molecular Hepatology.2023; 29(2): 384.     CrossRef
Discovery of tetrasubstituted thiophenes as Cisd2 activators: A potential novel therapeutic option in nonalcoholic fatty liver disease
Chun-Hsu Yao, Zhao-Qing Shen, Yesudoss Christu Rajan, Yu-Wen Huang, Chin-Yu Lin, Jen-Shin Song, Hui-Yi Shiao, Yi-Yu Ke, Yu-Shiou Fan, Chi-Hui Tsai, Teng-Kuang Yeh, Ting-Fen Tsai, Jinq-Chyi Lee
European Journal of Medicinal Chemistry.2023; 258: 115583.     CrossRef
Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”
Seogsong Jeong, Yohwan Lim, Su Kyoung Lee, Hyun Wook Han
Clinical and Molecular Hepatology.2023; 29(3): 810.     CrossRef
Raspberry ketone ameliorates nonalcoholic fatty liver disease in rats by activating the AMPK pathway
Mervat E. Askar, Sousou I. Ali, Nahla N. Younis, Mohamed A. Shaheen, Mahmoud E. Zaher
European Journal of Pharmacology.2023; 957: 176001.     CrossRef